The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Minister slams Lancet letter detailing Taiwan health system failings
04/26/2025 09:55 PM - Society
Aquarium owner receives jail time for importing protected animals
04/26/2025 09:49 PM - Politics
KMT vows to seek Lai recall after May 20 at large Taipei rally
04/26/2025 08:57 PM - Politics
Ex-Vice President Chen greets Biden, Japan's top diplomat at pope funeral
04/26/2025 08:57 PM - Culture
Taichung jam maker wins top accolade at annual U.K. marmalade event
04/26/2025 08:48 PM